Literature DB >> 21778211

Alternatively spliced androgen receptor variants.

Scott M Dehm1, Donald J Tindall.   

Abstract

Alternative splicing is an important mechanism for increasing functional diversity from a limited set of genes. Deregulation of this process is common in diverse pathologic conditions. The androgen receptor (AR) is a steroid receptor transcription factor with functions critical for normal male development as well as the growth and survival of normal and cancerous prostate tissue. Studies of AR function in androgen insensitivity syndrome (AIS) and prostate cancer (PCa) have demonstrated loss-of-function AR alterations in AIS and gain-of-function AR alterations in PCa. Over the past two decades, AR gene alterations have been identified in various individuals with AIS, which disrupt normal AR splicing patterns and yield dysfunctional AR protein variants. Recently, altered AR splicing patterns have been identified as a mechanism of PCa progression and resistance to androgen depletion therapy. Several studies have described the synthesis of alternatively spliced transcripts encoding truncated AR isoforms that lack the ligand-binding domain, which is the ultimate target of androgen depletion. Many of these truncated AR isoforms function as constitutively active, ligand-independent transcription factors that can support androgen-independent expression of AR target genes, as well as the androgen-independent growth of PCa cells. In this review, we will summarize the various alternatively spliced AR variants that have been discovered, with a focus on their role and origin in the pathologic conditions of AIS and PCa.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21778211      PMCID: PMC3235645          DOI: 10.1530/ERC-11-0141

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  57 in total

1.  Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations.

Authors:  P M Matias; P Donner; R Coelho; M Thomaz; C Peixoto; S Macedo; N Otto; S Joschko; P Scholz; A Wegg; S Bäsler; M Schäfer; U Egner; M A Carrondo
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

2.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Authors:  Shihua Sun; Cynthia C T Sprenger; Robert L Vessella; Kathleen Haugk; Kathryn Soriano; Elahe A Mostaghel; Stephanie T Page; Ilsa M Coleman; Holly M Nguyen; Huiying Sun; Peter S Nelson; Stephen R Plymate
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

3.  Interplay between two hormone-independent activation domains in the androgen receptor.

Authors:  Leen Callewaert; Nora Van Tilborgh; Frank Claessens
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

Review 4.  Nuclear receptor structure: implications for function.

Authors:  David L Bain; Aaron F Heneghan; Keith D Connaghan-Jones; Michael T Miura
Journal:  Annu Rev Physiol       Date:  2007       Impact factor: 19.318

Review 5.  Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions.

Authors:  David F Smith; David O Toft
Journal:  Mol Endocrinol       Date:  2008-05-01

6.  Novel point mutation in the splice donor site of exon-intron junction 6 of the androgen receptor gene in a patient with partial androgen insensitivity syndrome.

Authors:  I Sammarco; P Grimaldi; P Rossi; M Cappa; C Moretti; G Frajese; R Geremia
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

Review 7.  Molecular basis of androgen insensitivity.

Authors:  A O Brinkmann
Journal:  Mol Cell Endocrinol       Date:  2001-06-20       Impact factor: 4.102

8.  Androgen receptor function is modulated by the tissue-specific AR45 variant.

Authors:  Isabelle Ahrens-Fath; Oliver Politz; Christoph Geserick; Bernard Haendler
Journal:  FEBS J       Date:  2005-01       Impact factor: 5.542

Review 9.  The androgen receptor CAG repeat: a modifier of carcinogenesis?

Authors:  Paola Ferro; Maria G Catalano; Raffaella Dell'Eva; Nicoletta Fortunati; Ulrich Pfeffer
Journal:  Mol Cell Endocrinol       Date:  2002-07-31       Impact factor: 4.102

10.  Effect of a short CAG (glutamine) repeat on human androgen receptor function.

Authors:  Dacheng Ding; Lihua Xu; Mani Menon; G Prem Veer Reddy; Evelyn R Barrack
Journal:  Prostate       Date:  2004-01-01       Impact factor: 4.104

View more
  176 in total

1.  Foxa2 activates the transcription of androgen receptor target genes in castrate resistant prostatic tumors.

Authors:  Zachary M Connelly; Shu Yang; Fenghua Chen; Yunshin Yeh; Nazih Khater; Renjie Jin; Robert Matusik; Xiuping Yu
Journal:  Am J Clin Exp Urol       Date:  2018-10-20

Review 2.  Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

Authors:  Cameron M Armstrong; Allen C Gao
Journal:  Am J Clin Exp Urol       Date:  2015-08-08

3.  AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.

Authors:  Gang Liu; Cynthia Sprenger; Shihua Sun; Kathryn Soriano Epilepsia; Kathleen Haugk; Xiaotun Zhang; Ilsa Coleman; Peter S Nelson; Stephen Plymate
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

4.  Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal.

Authors:  Siu Chiu Chan; Yingming Li; Scott M Dehm
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

5.  Maintenance of androgen receptor inactivation by S-nitrosylation.

Authors:  Yu Qin; Anindya Dey; Hamsa Thayele Purayil; Yehia Daaka
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

6.  Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer.

Authors:  Bin Wang; U-Ging Lo; Kaijie Wu; Payal Kapur; Xiangyang Liu; Jun Huang; Wei Chen; Elizabeth Hernandez; John Santoyo; Shi-Hong Ma; Rey-Chen Pong; Dalin He; Yi-Qiang Cheng; Jer-Tsong Hsieh
Journal:  Int J Cancer       Date:  2017-07-31       Impact factor: 7.396

7.  Nuclear βArrestin1 regulates androgen receptor function in castration resistant prostate cancer.

Authors:  Hamsa Thayele Purayil; Yushan Zhang; Joseph B Black; Raad Gharaibeh; Yehia Daaka
Journal:  Oncogene       Date:  2021-03-10       Impact factor: 9.867

8.  GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.

Authors:  Bin He; Rainer B Lanz; Warren Fiskus; Chuandong Geng; Ping Yi; Sean M Hartig; Kimal Rajapakshe; John Shou; Liping Wei; Shrijal S Shah; Christopher Foley; Sue Anne Chew; Vijay K Eedunuri; Diego J Bedoya; Qin Feng; Takashi Minami; Constantine S Mitsiades; Anna Frolov; Nancy L Weigel; Susan G Hilsenbeck; Daniel G Rosen; Timothy Palzkill; Michael M Ittmann; Yongcheng Song; Cristian Coarfa; Bert W O'Malley; Nicholas Mitsiades
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

Review 9.  Advancing precision medicine for prostate cancer through genomics.

Authors:  Sameek Roychowdhury; Arul M Chinnaiyan
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

Review 10.  Constitutive activity of the androgen receptor.

Authors:  Siu Chiu Chan; Scott M Dehm
Journal:  Adv Pharmacol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.